<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">A</forename><surname>Hochhaus</surname></persName>
							<email>andreas.hochhaus@med.uni-jena.de</email>
							<affiliation key="aff0">
								<orgName type="department">Abteilung Hämatologie/Onkologie</orgName>
								<orgName type="institution" key="instit1">Klinik für Innere Medizin II</orgName>
								<orgName type="institution" key="instit2">Universitätsklinikum Jena</orgName>
								<address>
									<settlement>Jena</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">G</forename><surname>Rosti</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Hematology and Oncology</orgName>
								<orgName type="institution">University of Bologna</orgName>
								<address>
									<settlement>Bologna</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ncp</forename><surname>Cross</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Faculty of Medicine</orgName>
								<orgName type="institution">University of Southampton</orgName>
								<address>
									<settlement>Southampton</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Steegmann</surname></persName>
							<affiliation key="aff3">
								<orgName type="institution" key="instit1">Hospital Universitario de la Princesa</orgName>
								<orgName type="institution" key="instit2">IIS-IP</orgName>
								<address>
									<settlement>Madrid</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">P</forename><surname>Le Coutre</surname></persName>
							<affiliation key="aff4">
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">G</forename><surname>Ossenkoppele</surname></persName>
							<affiliation key="aff5">
								<orgName type="institution">VU University Medical Center</orgName>
								<address>
									<settlement>Amsterdam</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">L</forename><surname>Petrov</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Ion Chiricuta Institute of Oncology</orgName>
								<address>
									<settlement>Cluj</settlement>
									<country key="RO">Romania</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">T</forename><surname>Masszi</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Department of Haematology and Stem Cell Transplantation</orgName>
								<orgName type="institution">St István and St László Hospital</orgName>
								<address>
									<settlement>Budapest</settlement>
									<country key="HU">Hungary</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">A</forename><surname>Hellmann</surname></persName>
							<affiliation key="aff8">
								<orgName type="institution">Medical University of Gdańsk</orgName>
								<address>
									<settlement>Gdańsk</settlement>
									<country key="PL">Poland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">L</forename><surname>Griskevicius</surname></persName>
							<affiliation key="aff9">
								<orgName type="institution" key="instit1">Vilnius University Hospital Santariskiu Klinikos</orgName>
								<orgName type="institution" key="instit2">Vilnius University</orgName>
								<address>
									<settlement>Vilnius</settlement>
									<country key="LT">Lithuania</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">W</forename><surname>Wiktor-Jedrzejczak</surname></persName>
							<affiliation key="aff10">
								<orgName type="department">Department of Hematology</orgName>
								<orgName type="institution">Medical University of Warsaw</orgName>
								<address>
									<settlement>Warsaw</settlement>
									<country key="PL">Poland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">D</forename><surname>Rea</surname></persName>
							<affiliation key="aff11">
								<orgName type="laboratory">Service d&apos;Hématologie Adulte et INSERM UMR1160</orgName>
								<orgName type="institution">Hôpital Saint-Louis</orgName>
								<address>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">D</forename><surname>Coriu</surname></persName>
							<affiliation key="aff12">
								<orgName type="institution">Fundeni Clinical Institute</orgName>
								<address>
									<settlement>Bucharest</settlement>
									<country key="RO">Romania</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">T</forename><forename type="middle">H</forename><surname>Brümmendorf</surname></persName>
							<affiliation key="aff13">
								<orgName type="institution">Universitätsklinikum RWTH Aachen</orgName>
								<address>
									<settlement>Aachen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">K</forename><surname>Porkka</surname></persName>
							<affiliation key="aff14">
								<orgName type="department">Department of Hematology</orgName>
								<orgName type="institution">Helsinki University Hospital Comprehensive Cancer Center</orgName>
								<address>
									<settlement>Helsinki</settlement>
									<country key="FI">Finland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">G</forename><surname>Saglio</surname></persName>
							<affiliation key="aff15">
								<orgName type="department">Division of Internal Medicine &amp; Hematology</orgName>
								<orgName type="institution">University of Turin</orgName>
								<address>
									<settlement>Orbassano</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">G</forename><surname>Gastl</surname></persName>
							<affiliation key="aff16">
								<orgName type="institution" key="instit1">Innere Medizin</orgName>
								<orgName type="institution" key="instit2">Medizinische Universität Innsbruck</orgName>
								<address>
									<settlement>Innsbruck</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Müller</surname></persName>
							<affiliation key="aff17">
								<orgName type="institution" key="instit1">Universitätsmedizin Mannheim</orgName>
								<orgName type="institution" key="instit2">University of Heidelberg</orgName>
								<address>
									<settlement>Mannheim</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">P</forename><surname>Schuld</surname></persName>
							<affiliation key="aff18">
								<orgName type="institution">Novartis Pharma AG</orgName>
								<address>
									<settlement>Basel</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Di</forename><surname>Matteo</surname></persName>
							<affiliation key="aff19">
								<orgName type="laboratory">Novartis Oncology Region Europe</orgName>
								<address>
									<settlement>Origgio</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">A</forename><surname>Pellegrino</surname></persName>
							<affiliation key="aff19">
								<orgName type="laboratory">Novartis Oncology Region Europe</orgName>
								<address>
									<settlement>Origgio</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">L</forename><surname>Dezzani</surname></persName>
							<affiliation key="aff19">
								<orgName type="laboratory">Novartis Oncology Region Europe</orgName>
								<address>
									<settlement>Origgio</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">F-X</forename><surname>Mahon</surname></persName>
							<affiliation key="aff20">
								<orgName type="laboratory">Laboratoire Hématopoïèse Leucémique et Cible Thérapeutique</orgName>
								<orgName type="institution">Université Victor Ségalen</orgName>
								<address>
									<settlement>Bordeaux</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Baccarani</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Hematology and Oncology</orgName>
								<orgName type="institution">University of Bologna</orgName>
								<address>
									<settlement>Bologna</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Giles</surname></persName>
							<affiliation key="aff21">
								<orgName type="department">Northwestern Medicine Developmental Therapeutics Institute</orgName>
								<orgName type="institution">Robert H. Lurie Comprehensive Cancer Center of Northwestern University</orgName>
								<address>
									<settlement>Chicago</settlement>
									<region>IL</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff22">
								<orgName type="department">Abteilung Hämatologie/Onkologie</orgName>
								<orgName type="institution">Klinik für Innere Medizin II</orgName>
								<address>
									<settlement>Hochhaus</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff23">
								<orgName type="institution">Universitätsklinikum Jena</orgName>
								<address>
									<addrLine>Erlanger Allee 101</addrLine>
									<postCode>07740</postCode>
									<settlement>Jena</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">A6AC00CC1588FD5139C8546699DFEDDB</idno>
					<idno type="DOI">10.1038/leu.2015.270</idno>
					<note type="submission">Received 9 July 2015; revised 14 September 2015; accepted 18 September 2015; accepted article preview online 6 October 2015; advance online publication, 3 November 2015</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:16+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>The Evaluating Nilotinib Efficacy and Safety in Clinical Trials as First-Line Treatment (ENEST1st) study included 1089 patients with newly diagnosed chronic myeloid leukemia in chronic phase.</s><s>The rate of deep molecular response (MR 4 (BCR-ABL1 ⩽ 0.01% on the International Scale or undetectable BCR-ABL1 with ⩾ 10 000 ABL1 transcripts)) at 18 months was evaluated as the primary end point, with molecular responses monitored by the European Treatment and Outcome Study network of standardized laboratories.</s><s>This analysis was conducted after all patients had completed 24 months of study treatment (80.9% of patients) or discontinued early.</s><s>In patients with typical BCR-ABL1 transcripts and ⩽ 3 months of prior imatinib therapy, 38.4% (404/1052) achieved MR 4 at 18 months.</s><s>Six patients (0.6%) developed accelerated or blastic phase, and 13 (1.2%)</s><s>died.</s><s>The safety profile of nilotinib was consistent with that of previous studies, although the frequencies of some nilotinib-associated adverse events were lower (for example, rash, 21.4%).</s><s>Ischemic cardiovascular events occurred in 6.0% of patients.</s><s>Routine monitoring of lipid and glucose levels was not mandated in the protocol.</s><s>These results support the use of frontline nilotinib, particularly when achievement of a deep molecular response (a prerequisite for attempting treatment-free remission in clinical trials) is a treatment goal.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p><s>3]<ref type="bibr" target="#b4">[4]</ref><ref type="bibr" target="#b5">[5]</ref><ref type="bibr" target="#b6">[6]</ref><ref type="bibr" target="#b7">[7]</ref> ENESTnd met its primary end point, with statistically significantly higher rates of major molecular response (MMR; BCR-ABL1 ⩽ 0.1% on the International Scale (IS)) at 12 months with nilotinib 300 mg twice daily (44%) and nilotinib 400 mg twice daily (43%) than with imatinib (22%; P o0.001 vs either nilotinib arm). <ref type="bibr" target="#b5">5</ref></s><s>Moreover, progression to AP or blastic phase (BP) tended to be less common with nilotinib; by the 6-year data cutoff, 11 (nominal P = 0.0661 vs imatinib), 6 (nominal P = 0.0030 vs imatinib) and 21 patients in the nilotinib 300-mg twice-daily, nilotinib 400-mg twice-daily and imatinib arms, respectively, progressed to AP/BP on study. <ref type="bibr" target="#b6">6</ref></s><s>Although the total number of deaths on study was similar in the nilotinib 300-mg twice-daily and imatinib arms (by the 6-year data cutoff: nilotinib 300-mg twice-daily, 21; nilotinib 400-mg twice-daily, 11; imatinib, 23), fewer patients in the nilotinib arms than in the imatinib arm died owing to advanced CML (6, 4 and 16, respectively). <ref type="bibr" target="#b6">6</ref></s><s>he safety profile of nilotinib is distinct from that of imatinib.</s><s>4]<ref type="bibr" target="#b5">[5]</ref><ref type="bibr" target="#b6">[6]</ref><ref type="bibr" target="#b7">[7]</ref> In contrast to the trend for fewer deaths with the higher dose of nilotinib vs the lower dose, cardiovascular events were less common with the lower nilotinib dose. <ref type="bibr" target="#b6">6</ref></s><s>NEST1st was a phase 3b, multicenter, single-arm, open-label study investigating the efficacy and safety of nilotinib 300 mg twice daily (the recommended starting dose for patients with newly diagnosed CML-CP 1 ) in a large population of patients with newly diagnosed Ph+ or Ph− BCR-ABL1+ CML-CP.</s><s>Because achievement of a deep molecular response is a key eligibility criterion for attempting treatment-free remission (TFR) in clinical trials, <ref type="bibr" target="#b8">[8]</ref><ref type="bibr" target="#b9">[9]</ref><ref type="bibr" target="#b10">[10]</ref><ref type="bibr" target="#b11">[11]</ref><ref type="bibr" target="#b12">[12]</ref><ref type="bibr" target="#b13">[13]</ref> ENEST1st was designed with an emphasis on evaluating rates of deep molecular responses achieved with frontline nilotinib.</s><s>Although the most appropriate depth of response (for example, molecular response 4 (MR <ref type="bibr" target="#b4">4</ref> ; BCR-ABL1 IS ⩽ 0.01%), molecular response 4.5 (MR <ref type="bibr">4.5</ref> ; BCR-ABL1 IS ⩽ 0.0032%) or deeper) at which to attempt TFR remains unknown, TFR following achievement of sustained MR 4 is being investigated in ongoing studies <ref type="bibr" target="#b12">12,</ref><ref type="bibr" target="#b13">13</ref> ; thus the ENEST1st primary end point analysis (rate of MR 4 at 18 months) provides an indication of the proportion of nilotinib-treated patients who could be expected to meet the eligibility requirements for such studies.</s><s>In addition to evaluating deep molecular responses, ENEST1st was the first study to evaluate the association between baseline European Treatment and Outcome Study (EUTOS) risk score <ref type="bibr" target="#b14">14</ref> and nilotinib efficacy and the first study to conduct molecular monitoring using a network of IS-standardized laboratories, with 14 EUTOS laboratories participating.</s><s>Here the final results of ENEST1st are reported, based on analyses conducted after all patients completed 24 months of study treatment or discontinued early.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients, study design and treatments</head><p><s>Adults (aged ⩾ 18 years) with newly diagnosed (⩽6 months), cytogenetically confirmed Ph+ CML-CP or Ph− BCR-ABL1+ CML-CP were eligible for enrollment.</s><s>World Health Organization performance status ⩽ 2 was required.</s><s>Patients previously treated with hydroxyurea for 46 months and imatinib for 43 months were excluded.</s><s>Patients were also excluded if they had known impairments in cardiac function (including left ventricular ejection fraction o45%, complete left bundle branch block, right bundle branch block plus left anterior hemiblock/bifascicular block, ventricularpaced pacemaker, congenital long QT syndrome, history or presence of clinically significant ventricular or atrial tachyarrhythmia, clinically significant resting bradycardia, QTcF 4 450 ms, myocardial infarction within the past 12 months or other clinically significant heart disease), history of acute or chronic pancreatitis, impaired gastrointestinal function, concurrent uncontrolled medical conditions that would present unacceptable safety risks or compromise compliance with the protocol, major surgery within the past 2 weeks or not recovered from side effects of surgery or concomitant treatment with medications with the potential to prolong the QT interval or known to be strong inducers or inhibitors of cytochrome P450 3A4.</s></p><p><s>All enrolled patients were treated with nilotinib at a starting dose of 300 mg twice daily, for up to 24 months.</s><s>Dose escalation was not allowed.</s><s>Dose interruptions were recommended for patients with study drugrelated, clinically significant, nonhematological, noncardiac grade 2/3 AEs or study drug-related grade 3/4 events related to white blood cells or platelets.</s><s>Recommendations for treatment resumption/dose reduction were as follows: following the first and second occurrences, resume treatment with nilotinib 600 mg/day upon improvement to grade o 2 (nonhematological) or o3 (hematological); following the third occurrence, resume treatment with nilotinib 450 mg/day upon improvement to grade o2 (nonhematological) or o3 (hematological), escalating to 600 mg/day after 1 week; following the fourth occurrence, resume treatment with nilotinib 300 mg/day upon improvement to grade o2 (nonhematological) or o3 (hematological), escalating to 600 mg/day after 1 month (escalation for hematological events only); following the fifth occurrence (or following any study drug-related, clinically significant, nonhematological grade 4 AE), stop treatment and contact the study management committee.</s><s>For patients with corrected QT interval (QTc) prolongation from 480 to 499 ms, nilotinib dose interruption followed by resumption at 450 mg/day upon improvement to QTc ⩽ 450 ms was recommended; for patients with QTc prolongation to ⩾ 500 ms or with significant cardiac conduction or rhythm abnormalities, permanent discontinuation of nilotinib was recommended.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Assessments</head><p><s>BCR-ABL1 transcript type was determined by multiplex PCR at baseline. <ref type="bibr" target="#b15">15</ref></s><s>olecular responses were assessed every 3 months during study treatment using real-time quantitative PCR (RQ-PCR) at designated EUTOS laboratories standardized to the IS.</s><s>Deep molecular responses were scored in accordance with the EUTOS recommendations in place at the time. <ref type="bibr" target="#b16">16</ref></s><s>R <ref type="bibr" target="#b4">4</ref> was defined as detectable BCR-ABL1 IS ⩽ 0.01% or undetectable BCR-ABL1 in samples with ⩾ 10 000 ABL1 transcripts.</s><s>Samples with a mean of o10 000 ABL1 transcripts, or with a total of o10 000 ABL1 transcripts in the case of undetectable BCR-ABL1, were considered unevaluable for MR <ref type="bibr" target="#b4">4</ref> .</s><s>MR <ref type="bibr">4.5</ref> was defined as detectable BCR-ABL1 IS ⩽0.0032% or undetectable BCR-ABL1 in samples with ⩾32 000 ABL1 transcripts.</s><s>Samples with a mean of o 32 000 ABL1 transcripts, or with a total of o32 000 ABL1 transcripts in the case of undetectable BCR-ABL1, were considered unevaluable for MR <ref type="bibr">4.5</ref> . <ref type="bibr" target="#b16">16</ref></s><s>one marrow cytogenetic assessments were performed ⩽ 8 weeks before the first dose of nilotinib and at months 3 and 6 and every 6 months thereafter until MMR was achieved or the patient discontinued nilotinib.</s><s>Cytogenetic assessments were performed and analyzed locally using standard methods; fluorescence in situ hybridization analyses were not allowed.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>End points and definitions</head><p><s>The primary end point was the rate of MR 4 at 18 months.</s><s>Secondary end points included the rates of complete cytogenetic response (CCyR; 0% Ph+ metaphases), MMR, MR <ref type="bibr" target="#b4">4</ref> and MR <ref type="bibr">4.5</ref> at and by 12 and 24 months; progression to AP/BP; progression-free survival; overall survival (OS); and safety.</s><s>Patients who discontinued study treatment early were followed for survival for up to 24 months; data regarding other outcomes (including progression) were not collected after discontinuation of study treatment.</s><s>Progression-free survival was defined as the time from the first dose of study treatment until documented disease progression or death owing to any cause.</s><s>OS was defined as the time from the first dose of study treatment until death owing to any cause at any time (including after discontinuation of study treatment).</s><s>Patients were monitored for AEs throughout study treatment and for up to 28 days following the last dose of study drug.</s><s>AEs were assessed according to the Common Terminology Criteria for Adverse Events version 4.0. 17</s><s>AE types included in the definition of ischemic cardiovascular events (subdivided into three groups: peripheral artery disease, ischemic heart disease, and ischemic cerebrovascular events) are detailed in Supplementary Table <ref type="table" target="#tab_1">S1</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analyses</head><p><s>All patients who received ⩾ 1 dose of study treatment were included in the intent-to-treat and safety populations.</s><s>Patients with typical BCR-ABL1 transcripts (that is, b2a2 and/or b3a2) and ⩽3 months of prior imatinib treatment were included in the molecular analysis population for evaluating molecular response rates (patients with atypical BCR-ABL1 transcripts were excluded because standard RQ-PCR methodology was not optimized for detection of atypical BCR-ABL1 transcripts; patients with 43 months of imatinib therapy (a protocol violation) were excluded to be as conservative as possible in analyzing the efficacy of frontline nilotinib by avoiding potential confounding effects of prior imatinib).</s><s>Patients with typical BCR-ABL1 transcripts, no prior imatinib exposure and evaluable RQ-PCR assessments at 3 months were included in the landmark analysis population; patients who had already achieved the target response (MMR, MR <ref type="bibr" target="#b4">4</ref> or MR <ref type="bibr">4.5</ref> , respectively) at 3 months were excluded from the landmark analyses of MMR, MR <ref type="bibr" target="#b4">4</ref> and MR <ref type="bibr">4.5</ref> rates over time.</s><s>Patients with Ph+ metaphases detected at screening or without evaluable cytogenetic analyses at screening but with Ph+ metaphases detected at a later time point were included in the cytogenetic analysis population for evaluating rates of CCyR (patients without confirmed Ph+ disease were unevaluable for CyR and were excluded from the analysis of CCyR rates).</s></p><p><s>For calculation of response rates 'at' a designated time point, patients were considered responders only if an assessment at that time point showed achievement of the response.</s><s>Response rates 'by' a designated time point were calculated as cumulative response rates, counting all patients with a response detected at or before the specified time point as responders.</s><s>All response rates were calculated as raw proportions.</s><s>Rates of freedom from progression to AP/BP on treatment and OS were estimated using Kaplan-Meier product limit estimates according to intent-to-treat principles.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ethics</head><p><s>ENEST1st was conducted in accordance with the International Conference on Harmonisation Harmonised Tripartite Guidelines for Good Clinical Practice, the Declaration of Helsinki and applicable local regulations.</s><s>Eligible patients were included only after providing written consent and in accordance with local laws and regulations.</s><s>The protocol and informed consent forms were reviewed and approved by an institutional review board, independent ethics committee or research ethics board before study start at each participating institution.</s><s>ENEST1st was registered in the EU Clinical Trials Registry (2009-017775-19) and ClinicalTrials.gov</s><s>(NCT01061177).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ENEST1st study of frontline nilotinib in CML</head><p><s>A Hochhaus et al</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients and treatment exposure</head><p><s>From 2010 to 2012, 1164 patients were screened, 1091 were enrolled from 307 sites in 26 European countries (Supplementary Figure <ref type="figure" target="#fig_0">S1</ref>; Supplementary Table <ref type="table" target="#tab_2">S2</ref>) and 1089 received ⩾ 1 dose of nilotinib 300 mg twice daily (Figure <ref type="figure" target="#fig_0">1</ref>).</s><s>The median age of treated patients was 53 years (Table <ref type="table" target="#tab_1">1</ref>).</s><s>The median time since diagnosis was 0.9 months, and 70.3% of patients (n = 766) had received prior treatment for CML (hydroxyurea, 52.9% (n = 576); imatinib, 17.3% (n = 188); other, 0.2% (n = 2)).</s><s>EUTOS risk scores were low and high in 82.6% (n = 900) and 8.6% (n = 94) of patients, respectively; Sokal risk scores were low, intermediate and high in 34.6% (n = 377), 37.5% (n = 408) and 18.1% (n = 197), respectively.</s><s>EUTOS and Sokal risk scores could not be calculated in 8.7% (n = 95) and 9.8% (n = 107) of patients, respectively, owing to missing baseline data for ⩾ 1 parameter required for the calculation.</s><s>A total of 80.9% of patients (n = 881) completed 24 months of study treatment, and 19.1% (n = 208) discontinued before 24 months (Table <ref type="table" target="#tab_2">2</ref>).</s><s>Dose changes or interruptions occurred in 45.2% of patients (n = 492), including 36.7% (n = 400) with changes or interruptions owing to AEs or laboratory abnormalities.</s></p><p><s>Molecular and cytogenetic responses Among patients in the molecular analysis population (n = 1052), the rate of MR 4 at 18 months was 38.4% (95% confidence interval (CI), 35.5-41.3%;</s><s>n = 404).</s><s>Rates of MMR, MR <ref type="bibr" target="#b4">4</ref> and MR 4.5 at 3, 12, 18 and 24 months are listed in Table <ref type="table" target="#tab_3">3</ref>. Cumulative rates of MMR, MR <ref type="bibr" target="#b4">4</ref> and MR 4.5 by 24 months were 80.4% (n = 846), 55.2% (n = 581) and 38.6% (n = 406), respectively (Figure <ref type="figure" target="#fig_1">2a</ref>).</s><s>Among patients remaining on study at 18 and 24 months, 13.7% (121/886) and 9.2% (79/855) had not achieved MMR by 18 or 24 months, respectively.</s></p><p><s>Patients with low EUTOS or Sokal risk scores were more likely than those with higher scores to achieve MR <ref type="bibr" target="#b4">4</ref> (Figure <ref type="figure" target="#fig_1">2b</ref>).</s><s>At 24 months, MR <ref type="bibr" target="#b4">4</ref>  Among patients in the molecular analysis population with no prior imatinib exposure (n = 872), 81.2% (n = 708), 55.5% (n = 484) and 37.8% (n = 330) achieved MMR, MR <ref type="bibr" target="#b4">4</ref> and MR <ref type="bibr">4.5</ref> , respectively, by 24 months.</s><s>Of patients in this subpopulation with evaluable 3month RQ-PCR assessments (n = 783; landmark analysis population), 78.5% (n = 615), 18.5% (n = 145) and 2.9% (n = 23) had BCR-ABL1 IS ⩽ 1%, BCR-ABL1 IS 41-⩽ 10% and BCR-ABL1 IS 410%, respectively, at 3 months.</s><s>Rates of MMR, MR <ref type="bibr" target="#b4">4</ref> and MR 4.5 by 24 months were the highest among patients with BCR-ABL1 IS ⩽ 1% at 3 months (excluding those with MMR (n = 241), MR <ref type="bibr" target="#b4">4</ref> (n = 46) or MR <ref type="bibr">4.5</ref> (n = 14), respectively, at 3 months) and the lowest among patients with BCR-ABL1 IS 410% at 3 months (Figure <ref type="figure">3</ref>).</s></p><p><s>Patients in the intent-to-treat population with documented Ph− BCR-ABL1+ disease at screening (n = 30) or with unconfirmed Ph status at screening and no Ph+ metaphases detected at later time points (n = 76) were excluded from the cytogenetic analysis population.</s><s>Among the remaining patients (n = 983), 67.3% (95% CI, 64.4-70.3%;</s><s>n = 662) achieved CCyR by 6 months and 82.5% (95% CI, 80.1-84.9%;</s><s>n = 811) achieved CCyR by 12 months.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Survival and progression</head><p><s>Estimated OS at 24 months was 98.9% (95% CI, 98.0-99.4%),</s><s>with 13 deaths reported on study (⩽24 months after first dose of study treatment).</s><s>Four patients died ⩽ 28 days after the last dose of study treatment/month 24 evaluation (one each due to pulmonary embolism, congestive heart failure, thrombocytopenia and infection), and nine patients died 428 days after the last dose of study treatment/month 24 evaluation (three each due to infections and secondary cancers and one each due to cerebral infarction, heart failure and CML progression).</s><s>Six patients (0.6%) progressed to AP (n = 3) or BP (n = 3) on treatment, none of whom The original target enrollment of N = 806 (determined using an approximation of a normal distribution to achieve a precision of 3.3% for the 95% CI of the primary end point, assuming an MR <ref type="bibr" target="#b4">4</ref>   Includes discontinuations owing to protocol deviation (n = 11), loss to follow-up (n = 9), new cancer therapy (n = 9; chronic myeloid leukemia (n = 7) and endometrial cancer and non-Hodgkin lymphoma (n = 1 each)), administrative problems (n = 4) and death (n = 4).</s><s>d Excluding periods of drug interruption.</s><s>e Defined as the sum of all doses administered divided by the time on treatment (including periods of drug interruption).</s><s>f Reasons for dosing error and scheduling conflict included commercial drug dispensed or delayed medication return by patient.</s><s>Abbreviations: CI, confidence interval; MMR, major molecular response (BCR-ABL1 IS ⩽ 0.1%); MR <ref type="bibr" target="#b4">4</ref> , molecular response 4 (BCR-ABL1 IS ⩽ 0.01%); MR <ref type="bibr">4.5</ref> , molecular response 4.5 (BCR-ABL1 IS ⩽ 0.0032%).</s></p><p><s>3.4% (n = 37; grade 3/4, 2.2%) and ischemic cerebrovascular events in 0.8% (n = 9; grade 3/4, 0.6%).</s><s>Four patients died due to ischemic cardiovascular events, one each due to congestive heart failure, cerebral infarction, heart failure and ischemic stroke (the death due to ischemic stroke occurred 424 months after first dose of study drug; therefore, it was not considered in the OS analysis).</s><s>Grade 3/4 thrombocytopenia and neutropenia were reported in 6.0% (n = 65) and 4.8% (n = 52) of patients, respectively (Table <ref type="table" target="#tab_8">5</ref>).</s><s>Grade 3/4 biochemical abnormalities of decreased phosphate level and increased lipase activity occurred in 14.3% (n = 156) and 7.2% (n = 78) of patients, respectively.</s></p><p><s>Because routine monitoring of lipid and glucose levels was not mandated in the study protocol, the frequencies of hypercholesterolemia, hyperglycemia and diabetes mellitus on study could not be evaluated; however, AEs of hypercholesterolemia, hyperglycemia and diabetes mellitus were spontaneously reported in 3.0% (n = 33), 3.3% (n = 36) and 1.2% (n = 13) of patients, respectively.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p><s>ENEST1st was the first study to investigate deep molecular response as the primary end point.</s><s>Results from this study confirm the high rates of deep responses achieved with frontline nilotinib; 38.4% of patients in the molecular analysis population achieved the primary end point of MR 4 at 18 months, and by 24 months, 55.2% achieved MR <ref type="bibr" target="#b4">4</ref> and 38.6% achieved MR <ref type="bibr">4.5</ref> .</s><s>Although the most appropriate molecular response threshold for attempting TFR remains under investigation, the feasibility of TFR following achievement of a sustained, deep molecular response on nilotinib has been demonstrated, <ref type="bibr" target="#b11">11</ref> and ongoing studies are evaluating TFR in patients with sustained MR <ref type="bibr" target="#b4">4</ref> or MR <ref type="bibr">4.5</ref> on nilotinib. <ref type="bibr" target="#b12">12,</ref><ref type="bibr" target="#b13">13</ref></s><s>The high rates of MR 4 and MR <ref type="bibr">4.5</ref> in ENEST1st suggest that many patients treated with frontline nilotinib may be able to achieve the level of response necessary to qualify for such studies.</s></p><p><s>9]<ref type="bibr" target="#b20">[20]</ref> In a recent study of patients treated with frontline imatinib, those with MR 4 at 24 months had a 0% estimated incidence of leukemia-related death by 6 years vs 7% for patients without MR 4 at 24 months (P = 0.004). <ref type="bibr" target="#b21">21</ref></s><s>]<ref type="bibr" target="#b5">[5]</ref><ref type="bibr" target="#b6">[6]</ref><ref type="bibr" target="#b7">[7]</ref> The use of the EUTOS laboratory network to assess molecular responses in ENEST1st demonstrated the feasibility of noncentralized, regional molecular monitoring, provided that standardized and sensitive assays are used and definitions are harmonized. <ref type="bibr" target="#b16">16</ref></s><s>Through the work of the EUTOS Study Group, recommendations for standardized scoring of deep molecular responses have been developed, which will allow for more consistent patient management across local and regional treatment centers. <ref type="bibr" target="#b23">23</ref></s><s>As ENEST1st was the first study to assess nilotinib efficacy according to EUTOS risk scores, these results validate the use of this newer risk score for assessing patient prognosis at baseline. <ref type="bibr" target="#b14">14</ref></s><s>Importantly, data from a EUTOS population-based registry of 2904 patients with CML (94.3% with CML-CP) suggest that the age, sex and EUTOS risk score distribution of patients in ENEST1st were generally similar to what is observed in routine clinical practice. <ref type="bibr" target="#b24">24</ref></s><s>atients in ENEST1st were slightly older than those in the nilotinib 300-mg twice-daily arm of ENESTnd (median age of 53 years in ENEST1st vs 47 years in ENESTnd); however, the distribution of Sokal risk scores was similar (72% of patients in each study had low or intermediate Sokal risk scores). <ref type="bibr" target="#b5">5</ref></s><s>Nonetheless, molecular response rates were higher in ENEST1st than in ENESTnd; in ENEST1st, 81, 56 and 38% of patients without prior imatinib exposure (the subpopulation most comparable to patients in ENESTnd) achieved MMR, MR <ref type="bibr" target="#b4">4</ref> and MR <ref type="bibr">4.5</ref> , respectively, by 2 years, compared with 71, 39 and 25% of patients, respectively, in the nilotinib 300-mg twice-daily arm of ENESTnd. <ref type="bibr" target="#b4">4</ref> This difference may be due in part to improvements in the management of nilotinib-treated patients, that is, a learning effect in the period since ENESTnd was initiated (in 2007). <ref type="bibr" target="#b5">5</ref></s><s>For example, whereas the ENESTnd protocol called for dose reduction to nilotinib 400 mg once daily after the first or second occurrence of study drug-related AEs, and permanent discontinuation after the next occurrence, <ref type="bibr" target="#b5">5</ref> new dose reduction guidelines in ENEST1st allowed for stepwise or temporary dose reductions to nilotinib 450 or 300 mg daily in patients with recurrent AEs, which may have enabled patients to receive a more optimal nilotinib dose.</s><s>In the nilotinib 300-mg twice-daily arm of ENESTnd, 55% of patients had dose interruptions/reductions owing to AEs by the 2-year data cutoff, and the median dose intensity was 594 mg/day (25th-75th percentile, 553-600 mg/day). <ref type="bibr" target="#b4">4</ref></s><s>By comparison, 36.7% of patients in ENEST1st had dose changes or interruptions owing to AEs/ laboratory abnormalities, and the 25th percentile for dose intensity was 35 mg/day higher than that in ENESTnd.</s><s>Consistent with prior studies, <ref type="bibr" target="#b2">2,</ref><ref type="bibr" target="#b25">[25]</ref><ref type="bibr" target="#b26">[26]</ref><ref type="bibr" target="#b27">[27]</ref> ENEST1st demonstrated the importance of early molecular response to frontline treatment.</s><s>Patients with BCR-ABL1 IS ⩽ 1% at 3 months achieved the highest rates of response at later time points, whereas no patient with BCR-ABL1 IS 410% at 3 months achieved MR 4 by 24 months.</s><s>Because of the known association between early molecular response and long-term outcomes, both the European Leukemia-Net and the National Comprehensive Cancer Network recommend BCR-ABL1 IS ⩽ 10% as a target response at 3 months. <ref type="bibr" target="#b28">28,</ref><ref type="bibr" target="#b29">29</ref></s><s>Nearly all patients (97%) in the ENEST1st landmark analysis population achieved this target, consistent with results from ENESTnd. <ref type="bibr" target="#b2">2</ref> Although achievement of BCR-ABL1 IS ⩽ 1% at 3 months is not a designated treatment goal in current CML guidelines, <ref type="bibr" target="#b28">28,</ref><ref type="bibr" target="#b29">29</ref> the results reported here are consistent with those reported elsewhere in demonstrating the value of this landmark for predicting future achievement of deep molecular response. <ref type="bibr" target="#b2">2,</ref><ref type="bibr" target="#b18">18</ref></s><s>1]<ref type="bibr" target="#b32">[32]</ref> Branford et al. <ref type="bibr" target="#b31">31</ref> demonstrated that, among patients with BCR-ABL1 IS 410% at 3 months, those with a BCR-ABL1 halving time of 476 days had poorer long-term outcomes than those with a halving time of ⩽ 76 days, while Hanfstein et al. <ref type="bibr" target="#b30">30</ref> showed that the reduction in BCR-ABL1 transcript levels at 3 months relative to each patient's individual baseline level was a significant predictor of survival.</s></p><p><s>Safety results from ENEST1st were similar to those of ENESTnd, <ref type="bibr" target="#b3">[3]</ref><ref type="bibr" target="#b4">[4]</ref><ref type="bibr" target="#b5">[5]</ref><ref type="bibr" target="#b6">[6]</ref><ref type="bibr" target="#b7">[7]</ref> with no new safety signals identified.</s><s>However, although patients in ENEST1st were older than patients in ENESTnd, <ref type="bibr" target="#b5">5</ref> the frequencies of some AEs, including rash and grade Figure <ref type="figure">3</ref>. Cumulative molecular response rates according to 3-month BCR-ABL1 IS .</s><s>(a) Raw cumulative rates (95% CI) of MMR (BCR-ABL1 IS ⩽ 0.1%), (b) MR <ref type="bibr" target="#b4">4</ref> (BCR-ABL1 IS ⩽ 0.01%) and (c) MR <ref type="bibr">4.5</ref> (BCR-ABL1 IS ⩽ 0.0032%) among patients in the landmark analysis population (n = 783) with BCR-ABL1 IS ⩽ 1%, 41-⩽ 10% and 410% at 3 months.</s><s>Patients who had already achieved MMR, MR <ref type="bibr" target="#b4">4</ref> or MR <ref type="bibr">4.5</ref> , respectively, at 3 months were excluded from the landmark analyses of MMR, MR <ref type="bibr" target="#b4">4</ref> and MR <ref type="bibr">4.5</ref> rates over time.</s><s>3/4 thrombocytopenia and neutropenia, were lower in ENEST1st (reported frequencies in the nilotinib 300-mg twice-daily arm of ENESTnd by the 2-year data cutoff: rash, 41%; grade 3/4 thrombocytopenia, 10%; grade 3/4 neutropenia, 12%). <ref type="bibr" target="#b4">4</ref></s><s>]<ref type="bibr" target="#b35">[35]</ref> Although baseline cardiovascular risk factors were not collected in ENEST1st, the observed frequency of ischemic cardiovascular events (6%) was comparable to what has been previously reported for nilotinib-treated patients in ENESTnd. <ref type="bibr" target="#b6">6</ref></s><s>However, as some patients in ENESTnd experienced cardiovascular events at later time points (beyond the first 2 years of treatment), <ref type="bibr" target="#b6">6</ref> it is possible that the total frequency of such events in ENEST1st would increase with longer follow-up.</s><s>Nilotinib treatment is known to be associated with certain biochemical abnormalities, including hyperglycemia and hypercholesterolemia. <ref type="bibr" target="#b3">[3]</ref><ref type="bibr" target="#b4">[4]</ref><ref type="bibr" target="#b5">[5]</ref><ref type="bibr" target="#b6">[6]</ref><ref type="bibr" target="#b7">[7]</ref> Because glucose and lipid monitoring was not mandated in the ENEST1st protocol, the frequencies of glucose and lipid abnormalities are unknown; the rates of spontaneously reported hyperglycemia, hypercholesterolemia and diabetes mellitus likely underestimate the true frequency of these events.</s><s>For patients treated with nilotinib, it is recommended that lipid and glucose levels be monitored before initiating treatment and during treatment, and all cardiovascular risk factors should be monitored and actively managed according to standard guidelines. <ref type="bibr" target="#b0">1</ref> The high rates of response and very low rate of progression to AP/BP (0.6%) in ENEST1st demonstrate the efficacy of frontline nilotinib for the majority of patients; indeed, among patients remaining on treatment at 24 months, only 9.2% had not achieved MMR.</s><s>However, 19.1% of patients discontinued treatment before the 24-month assessment, clearly indicating that further improvements in the frontline management of patients with CML-CP are needed.</s><s>Overall, results from ENEST1st, including those reported here and data from 11 substudies directed by national and international study groups, provide further support for the use of nilotinib 300 mg twice daily as a frontline treatment option for patients with newly diagnosed CML-CP.</s><s>Glucose, cholesterol and lipid monitoring was not mandated by the protocol, and therefore, the frequencies of these abnormalities was unknown.</s><s>b Creatinine elevations were grade 1 (defined as 41-1.5-fold</s><s>baseline level or above the upper limit of normal to 1.5-fold the upper limit of normal <ref type="bibr" target="#b17">17</ref> ) in 71.0% of patients (n = 773).</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>•Figure 1 .</head><label>1</label><figDesc><div><p><s>Figure1.</s><s>Analysis populations.a</s><s>The original target enrollment of N = 806 (determined using an approximation of a normal distribution to achieve a precision of 3.3% for the 95% CI of the primary end point, assuming an MR<ref type="bibr" target="#b4">4</ref> rate of 25% at 18 months, a discontinuation rate of 15% and a Philadelphia chromosome-negative and/or atypical BCR-ABL1 transcript prevalence of 5%) was increased to allow a more robust analysis of the study's exploratory results.</s><s>ITT, intent to treat.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2 .</head><label>2</label><figDesc><div><p><s>Figure 2. Cumulative molecular response rates.</s><s>Raw cumulative incidence (95% CI) of (a) MMR (BCR-ABL1 IS ⩽ 0.1%), MR<ref type="bibr" target="#b4">4</ref> (BCR-ABL1 IS ⩽ 0.01%) and MR4.5  (BCR-ABL1 IS ⩽ 0.0032%) in the molecular analysis population (n = 1052) and (b) MR<ref type="bibr" target="#b4">4</ref> according to European Treatment and Outcome Study (EUTOS) and Sokal risk scores at diagnosis.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head></head><label></label><figDesc><div><p><s>rates (95% CI) among patients with low and high EUTOS risk scores were 41.4% (38.2-44.7%;</s><s>363/876) and 27.8% (18.5-37.0%;</s><s>25/90), respectively; MR 4 rates (95% CI) at 24 months were 44.7% (39.6-49.8%;</s><s>164/367), 39.7% (34.9-44.6%;</s><s>157/395), and 31.4% (24.8-38.0%;</s><s>60/191) among patients with low intermediate and high Sokal risk scores, respectively.</s></p></div></figDesc><table /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>rate of 25% at 18 months, a discontinuation rate of 15% and a Philadelphia chromosome-negative and/or atypical BCR-ABL1 transcript prevalence of 5%) was increased to allow a more robust analysis of the study's exploratory results.</s><s>ITT, intent to treat.</s><s>died on study.</s><s>At 24 months, the estimated rate of freedom from progression to AP/BP on treatment was 99.4% (95% CI, 98.7-99.7%).</s><s>Demographic and baseline characteristics (ITT population;</s></p></div></figDesc><table><row><cell>Safety</cell></row><row><cell>Rash, pruritus and headache were the most common nonhema-</cell></row><row><cell>tological AEs, reported in 21.4% (n = 233), 16.5% (n = 180) and</cell></row><row><cell>15.2% (n = 166) of patients, respectively (Table 4). Pancreatitis,</cell></row><row><cell>hepatotoxicity and fluid retention occurred in 1.0% (n = 11; grade</cell></row><row><cell>3/4, 0.6%), 1.4% (n = 15; grade 3/4, 0.4%) and 11.8% (n = 129; grade</cell></row><row><cell>3/4, 0.</cell></row></table><note><p><s>8%) of patients, respectively.Pleural effusion occurred in 0.6% (n = 7; grade 3/4, 0.2%) of patients; 1 patient with grade 3 pleural effusion was treated with imatinib before enrollment (imatinib duration, 53 days).No patient was diagnosed with pulmonary hypertension.Arrhythmia and supraventricular arrhythmia were reported in 0.6% (n = 6) and 0.1% (n = 1) of patients, respectively (including grade 3/4 arrhythmia in 1 patient).Congestive heart failure was reported in 0.3% of patients (n = 3; all grade 3).</s><s>Ischemic cardiovascular events occurred in 6.0% of patients (n = 65; grade 3/4, 3.5%), including peripheral artery disease in 1.9% (n = 21; grade 3/4, 0.7%), ischemic heart disease in Abbreviations: CML, chronic myeloid leukemia; EUTOS, European Treatment and Outcome Study; ITT, intent to treat; Ph, Philadelphia chromosome.</s><s>a One patient was pretreated with hydroxyurea while awaiting confirmation of CML diagnosis and, therefore, had a longer prior treatment duration than time since diagnosis.</s><s>Four patients with 43 months of prior exposure to imatinib were excluded from the analysis of median and range; for these 4 patients, prior treatment durations were 93, 114, 117 and ⩾ 1089 days, respectively.</s><s>b Among patients with prior CML treatments.</s><s>c Including e1a2, e19a2, e14a3, e18a2, e8a2 and e13a3.</s><s>d EUTOS and/or Sokal risk scores could not be calculated for patients with missing data for baseline parameters required for the calculation of these scores.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>Patient disposition and treatment exposure (safety</s></p></div></figDesc><table><row><cell>population; N = 1089)</cell><cell></cell></row><row><cell>Patients, n (%)</cell><cell>N = 1089</cell></row><row><cell>Completed ⩾ 24 months of treatment</cell><cell>881 (80.9)</cell></row><row><cell>Discontinued treatment a</cell><cell>208 (19.1)</cell></row><row><cell>Adverse event</cell><cell>117 (10.7)</cell></row><row><cell>Withdrew consent b</cell><cell>27 (2.5)</cell></row><row><cell>Disease progression/treatment failure</cell><cell>17 (1.6)</cell></row><row><cell>Abnormal laboratory value</cell><cell>6 (0.6)</cell></row><row><cell>Abnormal test procedure result</cell><cell>4 (0.4)</cell></row><row><cell>Other c</cell><cell>37 (3.4)</cell></row><row><cell>Median duration of exposure</cell><cell>722 (691-734)</cell></row><row><cell>(25th-75th percentile), days d</cell><cell></cell></row><row><cell>Median nilotinib dose intensity</cell><cell>600 (588-600)</cell></row><row><cell>(25th-75th percentile), mg/day e</cell><cell></cell></row><row><cell>Patients with dose interruption, n (%)</cell><cell>387 (35.5)</cell></row><row><cell>Median number of interruptions per patient</cell><cell>1 (1-2)</cell></row><row><cell>(25th-75th percentile)</cell><cell></cell></row><row><cell>Median duration of interruption (25th-75th</cell><cell>14 (7-30)</cell></row><row><cell>percentile), days</cell><cell></cell></row><row><cell>Patients with dose reduction, n (%)</cell><cell>321 (29.5)</cell></row><row><cell>Maximal dose reduction, n (%)</cell><cell></cell></row><row><cell>To 450 mg/day</cell><cell>22 (2.0)</cell></row><row><cell>To 400 mg/day</cell><cell>2 (0.2)</cell></row><row><cell>To 300 mg/day</cell><cell>263 (24.2)</cell></row><row><cell>To 150 mg/day</cell><cell>34 (3.1)</cell></row><row><cell cols="2">Total patients with dose change/interruption, n (%) 492 (45.2)</cell></row><row><cell>Reason for dose change/interruption</cell><cell></cell></row><row><cell>Adverse event/laboratory abnormality</cell><cell>400 (36.7)</cell></row><row><cell>Dosing error f</cell><cell>123 (11.3)</cell></row><row><cell>Scheduling conflict f</cell><cell>72 (6.6)</cell></row><row><cell>Dispensing error</cell><cell>32 (2.9)</cell></row></table><note><p><s>a Reasons for discontinuation are listed as reported by the investigator.b</s><s>Withdrawal of consent was due to treatment failure in 2 patients (1.8%).c</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 3 .</head><label>3</label><figDesc><div><p><s>4ates of MMR, MR4and MR 4.5 at 3, 12, 18 and 24 months</s></p></div></figDesc><table><row><cell cols="3">(molecular analysis population; n = 1052)</cell><cell></cell><cell></cell></row><row><cell></cell><cell>3 months</cell><cell>12 months</cell><cell>18 months</cell><cell>24 months</cell></row><row><cell>MMR, n (%)</cell><cell>312 (29.7)</cell><cell>592 (56.3)</cell><cell>692 (65.8)</cell><cell>644 (61.2)</cell></row><row><cell>95% CI</cell><cell>26.9-32.4</cell><cell>53.3-59.3</cell><cell>62.9-68.6</cell><cell>58.3-64.2</cell></row><row><cell>MR 4 , n (%)</cell><cell>66 (6.3)</cell><cell>324 (30.8)</cell><cell>404 (38.4)</cell><cell>425 (40.4)</cell></row><row><cell>95% CI</cell><cell>4.8-7.7</cell><cell>28.0-33.6</cell><cell>35.5-41.3</cell><cell>37.4-43.4</cell></row><row><cell>MR 4.5 , n (%)</cell><cell>20 (1.9)</cell><cell>161 (15.3)</cell><cell>220 (20.9)</cell><cell>231 (22.0)</cell></row><row><cell>95% CI</cell><cell>1.1-2.7</cell><cell>13.1-17.5</cell><cell>18.5-23.4</cell><cell>19.5-24.5</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>100 Cumulative Incidence of Response, % Time Since Study Entry, Months</head><label></label><figDesc></figDesc><table><row><cell></cell><cell>By 12 months</cell><cell>By 18 months</cell><cell>By 24 months</cell></row><row><cell>MMR</cell><cell></cell><cell>77.2% (74.7%-79.7%)</cell><cell>80.4% (78.0%-82.8%)</cell></row><row><cell>MR 4 MR 4.5</cell><cell>68.9% (66.1%-71.7%)</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>55.2%</cell></row><row><cell></cell><cell></cell><cell>48.7%</cell><cell>(52.2%-58.2%)</cell></row><row><cell></cell><cell></cell><cell>(45.6%-51.7%)</cell></row><row><cell></cell><cell>37.1%</cell><cell></cell></row><row><cell></cell><cell>(34.2%-40.0%)</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>38.6%</cell></row><row><cell></cell><cell></cell><cell>31.7%</cell><cell>(35.7%-41.5%)</cell></row><row><cell></cell><cell></cell><cell>(28.9%-34.6%)</cell></row><row><cell></cell><cell>20.7%</cell><cell></cell></row><row><cell></cell><cell>(18.3%-23.2%)</cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 4 .</head><label>4</label><figDesc><div><p><s>Nonhematological adverse events occurring in ⩾ 5.0% of patients at any grade or ⩾ 1% of patients at grade 3/4 (safety population; N = 1089)</s></p></div></figDesc><table><row><cell>Patients, n (%) a</cell><cell cols="4">Total (all grades) Grade 2 Grade 3 Grade 4</cell></row><row><cell>Rash</cell><cell>233 (21.4)</cell><cell cols="2">53 (4.9) 4 (0.4)</cell><cell>0</cell></row><row><cell>Pruritus</cell><cell>180 (16.5)</cell><cell cols="2">48 (4.4) 3 (0.3)</cell><cell>0</cell></row><row><cell>Headache</cell><cell>166 (15.2)</cell><cell cols="2">43 (3.9) 8 (0.7)</cell><cell>0</cell></row><row><cell>Abdominal pain</cell><cell>160 (14.7)</cell><cell cols="2">54 (5.0) 8 (0.7)</cell><cell>0</cell></row><row><cell>Fatigue</cell><cell>151 (13.9)</cell><cell cols="2">45 (4.1) 7 (0.6)</cell><cell>0</cell></row><row><cell>Nausea</cell><cell>123 (11.3)</cell><cell cols="2">37 (3.4) 5 (0.5)</cell><cell>0</cell></row><row><cell>Alopecia</cell><cell>115 (10.6)</cell><cell cols="2">15 (1.4) 1 (0.1)</cell><cell>0</cell></row><row><cell>Nasopharyngitis</cell><cell>113 (10.4)</cell><cell>28 (2.6)</cell><cell>0</cell><cell>0</cell></row><row><cell>Myalgia</cell><cell>99 (9.1)</cell><cell cols="2">20 (1.8) 3 (0.3)</cell><cell>0</cell></row><row><cell>Arthralgia</cell><cell>97 (8.9)</cell><cell cols="2">30 (2.8) 2 (0.2)</cell><cell>0</cell></row><row><cell>Asthenia</cell><cell>97 (8.9)</cell><cell cols="2">25 (2.3) 2 (0.2)</cell><cell>0</cell></row><row><cell>Diarrhea</cell><cell>94 (8.6)</cell><cell cols="2">22 (2.0) 2 (0.2)</cell><cell>0</cell></row><row><cell>Dry skin</cell><cell>93 (8.5)</cell><cell>19 (1.7)</cell><cell>0</cell><cell>0</cell></row><row><cell>Muscle spasms</cell><cell>93 (8.5)</cell><cell>13 (1.2)</cell><cell>0</cell><cell>0</cell></row><row><cell>Back pain</cell><cell>80 (7.3)</cell><cell cols="2">26 (2.4) 4 (0.4)</cell><cell>0</cell></row><row><cell>Constipation</cell><cell>67 (6.2)</cell><cell cols="2">21 (1.9) 1 (0.1)</cell><cell>0</cell></row><row><cell>Arterial hypertension</cell><cell>65 (6.0)</cell><cell cols="2">31 (2.8) 12 (1.1)</cell><cell>0</cell></row><row><cell>Vomiting</cell><cell>65 (6.0)</cell><cell cols="3">22 (2.0) 2 (0.2) 1 (0.1)</cell></row><row><cell>Cough</cell><cell>56 (5.1)</cell><cell cols="2">13 (1.2) 1 (0.1)</cell><cell>0</cell></row><row><cell>Insomnia</cell><cell>55 (5.1)</cell><cell cols="2">15 (1.4) 2 (0.2)</cell><cell>0</cell></row><row><cell>Pain in extremity</cell><cell>54 (5.0)</cell><cell cols="2">16 (1.5) 2 (0.2)</cell><cell>0</cell></row><row><cell cols="5">a Excluding events that started 428 days after last dose of study drug or</cell></row><row><cell>month 24.</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head>Cumulative Incidence of MMR, % Time Since Study Entry, Months</head><label></label><figDesc></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>88.5%</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">(85.3%-91.7%)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">By 12 months</cell><cell cols="2">By 18 months</cell><cell cols="2">By 24 months</cell></row><row><cell></cell><cell>100</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>, %</cell><cell>90</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Cumulative Incidence of MR 4</cell><cell>70 60 50 40 20 10 30 80</cell><cell></cell><cell></cell><cell cols="2">42.7% (38.6%-46.8%) 8.3% (3.8%-12.8%)</cell><cell cols="2">55.7% (51.6%-59.8%) 20.0% (13.5%-26.5%)</cell><cell cols="2">65.0% (61.1%-68.9%) 24.1% (17.2%-31.1%)</cell></row><row><cell></cell><cell>0</cell><cell></cell><cell></cell><cell></cell><cell>0%</cell><cell></cell><cell>0%</cell><cell></cell><cell>0%</cell></row><row><cell></cell><cell>0</cell><cell>3</cell><cell>6</cell><cell>9</cell><cell>12</cell><cell>15</cell><cell>18</cell><cell>21</cell><cell>24</cell></row><row><cell>, %</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Cumulative Incidence of MR 4.5</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_7"><head>Time Since Study Entry, Months Transcript Level at 3 Months</head><label></label><figDesc></figDesc><table><row><cell></cell><cell cols="4">BCR-ABL1 &gt; 0.01% to ≤ 1% (n = 569)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell cols="3">BCR-ABL1 &gt; 1% to ≤ 10% (n = 145)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell cols="3">BCR-ABL1 &gt; 10% (n = 23)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="4">Transcript Level at 3 Months</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell cols="4">BCR-ABL1 &gt; 0.0032% to ≤ 1% (n = 601)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell cols="3">BCR-ABL1 &gt; 1% to ≤ 10% (n = 145)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell cols="3">BCR-ABL1 &gt; 10% (n = 23)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>100</cell><cell></cell><cell></cell><cell cols="2">By 12 months</cell><cell cols="2">By 18 months</cell><cell cols="2">By 24 months</cell></row><row><cell>90</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>80</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>70</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>60</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>45.8%</cell></row><row><cell>50</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>38.1%</cell><cell cols="2">(41.8%-49.7%)</cell></row><row><cell>40</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">(34.2%-42.0%)</cell><cell></cell><cell></cell></row><row><cell>30</cell><cell></cell><cell></cell><cell cols="2">24.8% (21.3%-28.2%)</cell><cell></cell><cell></cell><cell></cell><cell>14.5%</cell></row><row><cell>20</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>9.0%</cell><cell cols="2">(8.8%-20.2%)</cell></row><row><cell>10</cell><cell></cell><cell></cell><cell cols="2">(0.9%-7.4%) 4.1%</cell><cell cols="2">(4.3%-13.6%)</cell><cell></cell><cell></cell></row><row><cell>0</cell><cell></cell><cell></cell><cell cols="2">0%</cell><cell></cell><cell>0%</cell><cell></cell><cell>0%</cell></row><row><cell>0</cell><cell>3</cell><cell>6</cell><cell>9</cell><cell>12</cell><cell>15</cell><cell>18</cell><cell>21</cell><cell>24</cell></row><row><cell></cell><cell></cell><cell cols="5">Time Since Study Entry, Months</cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_8"><head>Table 5 .</head><label>5</label><figDesc><div><p><s>Laboratory abnormalities (safety population; N = 1089) a</s></p></div></figDesc><table><row><cell></cell><cell>Total</cell><cell>Grade 2</cell><cell cols="2">Grade 3 Grade 4</cell></row><row><cell></cell><cell>(all grades)</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="3">Hematological laboratory abnormalities, n (%)</cell><cell></cell><cell></cell></row><row><cell>Anemia</cell><cell cols="3">774 (71.1) 116 (10.7) 15 (1.4)</cell><cell>0</cell></row><row><cell>Leukopenia</cell><cell>340 (31.2)</cell><cell>80 (7.3)</cell><cell>26 (2.4)</cell><cell>1 (0.1)</cell></row><row><cell>Lymphopenia</cell><cell cols="3">404 (37.1) 193 (17.7) 33 (3.0)</cell><cell>7 (0.6)</cell></row><row><cell>Neutropenia</cell><cell>208 (19.1)</cell><cell>71 (6.5)</cell><cell cols="2">32 (2.9) 20 (1.8)</cell></row><row><cell>Thrombocytopenia</cell><cell>438 (40.2)</cell><cell>51 (4.7)</cell><cell cols="2">41 (3.8) 24 (2.2)</cell></row><row><cell cols="3">Biochemical laboratory abnormalities, n (%)</cell><cell></cell><cell></cell></row><row><cell>Alanine</cell><cell>659 (60.5)</cell><cell>41 (3.8)</cell><cell>24 (2.2)</cell><cell>3 (0.3)</cell></row><row><cell>aminotransferase</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>increase</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Alkaline phosphatase</cell><cell>288 (26.4)</cell><cell>7 (0.6)</cell><cell>2 (0.2)</cell><cell>0</cell></row><row><cell>increase</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Amylase increase</cell><cell>177 (16.3)</cell><cell>24 (2.2)</cell><cell>15 (1.4)</cell><cell>0</cell></row><row><cell>Aspartate</cell><cell>356 (32.7)</cell><cell>15 (1.4)</cell><cell>10 (0.9)</cell><cell>1 (0.1)</cell></row><row><cell>aminotransferase</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>increase</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Calcium decrease</cell><cell>326 (29.9)</cell><cell>37 (3.4)</cell><cell cols="2">1 (0.1) 12 (1.1)</cell></row><row><cell>Calcium increase</cell><cell>69 (6.3)</cell><cell>0</cell><cell>0</cell><cell>1 (0.1)</cell></row><row><cell>Creatinine increase</cell><cell cols="2">818 (75.1) b 44 (4.0)</cell><cell>1 (0.1)</cell><cell>0</cell></row><row><cell>Lipase increase</cell><cell>315 (28.9)</cell><cell>53 (4.9)</cell><cell cols="2">66 (6.1) 12 (1.1)</cell></row><row><cell cols="2">Magnesium decrease 124 (11.4)</cell><cell>2 (0.2)</cell><cell>2 (0.2)</cell><cell>2 (0.2)</cell></row><row><cell>Magnesium increase</cell><cell>97 (8.9)</cell><cell>0</cell><cell>16 (1.5)</cell><cell>1 (0.1)</cell></row><row><cell>Phosphate decrease</cell><cell cols="4">685 (62.9) 466 (42.8) 148 (13.6) 8 (0.7)</cell></row><row><cell>Potassium decrease</cell><cell>136 (12.5)</cell><cell>0</cell><cell>9 (0.8)</cell><cell>0</cell></row><row><cell>Potassium increase</cell><cell>147 (13.5)</cell><cell>31 (2.8)</cell><cell>7 (0.6)</cell><cell>6 (0.6)</cell></row><row><cell>Sodium decrease</cell><cell>137 (12.6)</cell><cell>0</cell><cell>3 (0.3)</cell><cell>0</cell></row><row><cell>Sodium increase</cell><cell>72 (6.6)</cell><cell>3 (0.3)</cell><cell>1 (0.1)</cell><cell>1 (0.1)</cell></row><row><cell>Total bilirubin</cell><cell cols="3">599 (55.0) 243 (22.3) 34 (3.1)</cell><cell>0</cell></row><row><cell>increase</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Uric acid increase</cell><cell>255 (23.4)</cell><cell>0</cell><cell>0</cell><cell>17 (1.6)</cell></row></table><note><p><s>a</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Leukemia (2016) 57 -64 © 2016 Macmillan Publishers Limited</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">© 2016 Macmillan Publishers LimitedLeukemia (2016) 57 -64</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACKNOWLEDGEMENTS</head><p><s>We thank all physicians, study coordinators and documentation assistants for their active participation and cooperation.</s><s>In addition to the authors of this report, members of the Scientific Study Management Committee included Philippe Rousselot, MD and David Marin, MD; and members of the data management committee included Nelson Spector, MD, PhD and Armand Keating, MD, FRCP.</s><s>Financial support for medical editorial assistance was provided by Novartis Pharmaceuticals.</s><s>We thank Karen Kaluza, PhD, Jonathan Morgan, PhD and Karen Miller-Moslin, PhD (Articulate Science) for medical editorial assistance with this manuscript.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONFLICT OF INTEREST</head><p><s>Authors declare the following relationships with pharmaceutical companies: Novartis -receipt of honoraria (AHo, GR, NC, JS, PlC, TM, LG, WWJ, DR, DC, TB, GS, MM, FXM, MB, FG), research funding (all authors), nonfinancial support (GR, WWJ, DC, TB), employment (PS, PDM, AP, LD) and stock ownership (PS); Pfizer-receipt of honoraria (AHo, GR, JS, PlC, DR, DC, TB, GS, FXM, MB), research funding (AHo, GR, JS, TB) and nonfinancial support (GR, TB); Ariad-receipt of honoraria (AHo, GR, NC, JS, PlC, DR, TB, GS, MM, FXM, MB), research funding (AHo, GR, JS, MM) and nonfinancial support (GR, TB); Bristol-Myers Squibb-receipt of honoraria (AHo, GR, JS, PlC, TM, DR, DC, TB, GS, MM, FXM, MB), research funding (AHo, GR, JS, MM) and nonfinancial support (GR, TB).</s><s>This work is licensed under a Creative Commons Attribution 4.0 International License.</s><s>The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material.</s><s>To view a copy of this license, visit http://creativecommons.org/licenses/ by/4.0/</s><s>Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu)</s><s>ENEST1st study of frontline nilotinib in CML A Hochhaus et al</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<title/>
		<author>
			<persName><surname>Tasigna</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>package insert</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Novartis Pharmaceuticals Corporation: East Hanover</title>
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Hughes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Saglio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Kantarjian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Guilhot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Niederwieser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Rosti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="page" from="1353" to="1360" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Larson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hochhaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Hughes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Clark</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Etienne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Kim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="2197" to="2203" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Kantarjian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hochhaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Saglio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Souza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Flinn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">W</forename><surname>Stenke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="841" to="851" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia</title>
		<author>
			<persName><forename type="first">G</forename><surname>Saglio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Issaragrisil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Le Coutre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Etienne</forename><forename type="middle">G</forename><surname>Lobo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">362</biblScope>
			<biblScope unit="page" from="2251" to="2259" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Efficacy and safety of nilotinib vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase: 6-year follow-up of ENESTnd</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Hughes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Larson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Issaragrisil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Le Coutre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lobo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page">61</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>abstract P228</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">ENESTnd 5-year follow-up: continued benefit of frontline nilotinib (NIL) compared with imatinib (IM) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP)</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Hughes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Le Coutre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Jootar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Reiffers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Turkina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Saglio</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="236" to="237" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>abstract S677)</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">X</forename><surname>Mahon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Rea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Guilhot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Guilhot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Huguet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Nicolini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="1029" to="1035" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Ross</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Branford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Seymour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Schwarer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Arthur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">T</forename><surname>Yeung</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="page" from="515" to="522" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease</title>
		<author>
			<persName><forename type="first">P</forename><surname>Rousselot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Charbonnier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Cony-Makhoul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Agape</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">E</forename><surname>Nicolini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Varet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="424" to="430" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Dasatinib or nilotinib discontinuation in chronic phase (CP)-chronic myeloid leukemia (CML) patients (pts) with durably undetectable BCR-ABL transcripts: interim analysis of the STOP 2G-TKI study with a minimum follow-up of 12 months-on behalf of the French CML Group Filmc</title>
		<author>
			<persName><forename type="first">D</forename><surname>Rea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">E</forename><surname>Nicolini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tulliez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Rousselot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Guilhot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gardembas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">124</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>abstract 811</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Treatment-free remission (TFR) following nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom, ENESTop, ENESTgoal, and ENESTpath</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">X</forename><surname>Mahon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Baccarani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Mauro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Hughes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Saglio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Savona</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>abstract TPS7124)</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Interim analysis of a pan European Stop Tyrosine Kinase Inhibitor trial in chronic myeloid leukemia: the EURO-SKI study</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">X</forename><surname>Mahon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Richter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Guilhot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Muller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Dietz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Porkka</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">124</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>abstract 151</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score</title>
		<author>
			<persName><forename type="first">J</forename><surname>Hasford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Baccarani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Hoffmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Guilhot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Saussele</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Rosti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="page" from="686" to="692" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Cross</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">V</forename><surname>Melo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Goldman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="186" to="189" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Standardized definitions of molecular response in chronic myeloid leukemia</title>
		<author>
			<persName><forename type="first">Ncp</forename><surname>Cross</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>White</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Müller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Saglio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hochhaus</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="2172" to="2175" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<monogr>
		<title level="m" type="main">NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. National Cancer Institute</title>
		<imprint>
			<date type="published" when="2009">2009</date>
			<pubPlace>Bethesda, MD, USA</pubPlace>
		</imprint>
		<respStmt>
			<orgName>National Cancer Institute</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-Study IV</title>
		<author>
			<persName><forename type="first">R</forename><surname>Hehlmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Müller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lauseker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hanfstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fabarius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schreiber</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="415" to="423" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy</title>
		<author>
			<persName><forename type="first">G</forename><surname>Etienne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Dulucq</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">E</forename><surname>Nicolini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Morrisset</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Fort</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schmitt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="458" to="464" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors</title>
		<author>
			<persName><forename type="first">L</forename><surname>Falchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Kantarjian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Verma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Quintás-Cardama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>'brien</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Hematol</title>
		<imprint>
			<biblScope unit="volume">88</biblScope>
			<biblScope unit="page" from="1024" to="1029" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib</title>
		<author>
			<persName><forename type="first">F</forename><surname>Castagnetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Gugliotta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Breccia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Stagno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Iurlo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Albano</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="1823" to="1831" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV</title>
		<author>
			<persName><forename type="first">L</forename><surname>Kalmanti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Saussele</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lauseker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Müller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">T</forename><surname>Dietz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Heinrich</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="1123" to="1132" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Laboratory recommendations for scoring deep molecular response following treatment for chronic myeloid leukemia</title>
		<author>
			<persName><forename type="first">Ncp</forename><surname>Cross</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">E</forename><surname>White</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Colomer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ehrencrona</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Foroni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Gottardi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="999" to="1003" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European countries</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">S</forename><surname>Hoffmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Baccarani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hasford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Lindoerfer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Burgstaller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Sertic</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="1336" to="1343" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)</title>
		<author>
			<persName><forename type="first">B</forename><surname>Hanfstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Müller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hehlmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Erben</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lauseker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fabarius</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="2096" to="2102" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)</title>
		<author>
			<persName><forename type="first">E</forename><surname>Jabbour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Kantarjian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Saglio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Steegmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">P</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Boqué</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="page" from="494" to="500" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors</title>
		<author>
			<persName><forename type="first">D</forename><surname>Marin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Ibrahim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lucas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Gerrard</forename><forename type="middle">G</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Szydlo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="232" to="238" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">European LeukemiaNet recommendations for the management of chronic myeloid leukemia</title>
		<author>
			<persName><forename type="first">M</forename><surname>Baccarani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Deininger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Rosti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hochhaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Soverini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Apperley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="page" from="872" to="884" />
			<date type="published" when="2013">2013. 2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<monogr>
		<title level="m" type="main">NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia, v1., National Comprehensive Cancer Network</title>
		<imprint>
			<date type="published" when="2015">2015</date>
			<pubPlace>Fort Washington, PA, USA</pubPlace>
		</imprint>
		<respStmt>
			<orgName>National Comprehensive Cancer Network</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib</title>
		<author>
			<persName><forename type="first">B</forename><surname>Hanfstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Shlyakhto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lauseker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hehlmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Saussele</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Dietz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="1988" to="1992" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Prognosis for patients with CML and 410% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline</title>
		<author>
			<persName><forename type="first">S</forename><surname>Branford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">T</forename><surname>Yeung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">T</forename><surname>Parker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">D</forename><surname>Roberts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Purins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Braley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">124</biblScope>
			<biblScope unit="page" from="511" to="518" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Very early molecular responses in the first two months of therapy are highly predictive of deep molecular responses at 18 months, in chronic myeloid leukemia patients treated upfront with nilotinib</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Steegmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Casado</forename><surname>Montero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">F</forename><surname>Gómez-Casares</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Rozman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Echeveste</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Garcia-Gutierrez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page">75</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>abstract P281)</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Pancreatic cancer and FOLFIR-INOX: a new era and new questions</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Marsh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Talamonti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Katz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Herman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Med</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="853" to="863" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Welsh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Corrie</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ther Adv Med Oncol</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="122" to="136" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Dooley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gupta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bhattacharyya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Middleton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ther Adv Med Oncol</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="262" to="266" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
